Your browser doesn't support javascript.
loading
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
Haikala, Heidi M; Lopez, Timothy; Köhler, Jens; Eser, Pinar O; Xu, Man; Zeng, Qing; Teceno, Tyler J; Ngo, Kenneth; Zhao, Yutong; Ivanova, Elena V; Bertram, Arrien A; Leeper, Brittaney A; Chambers, Emily S; Adeni, Anika E; Taus, Luke J; Kuraguchi, Mari; Kirschmeier, Paul T; Yu, Channing; Shiose, Yoshinobu; Kamai, Yasuki; Qiu, Yang; Paweletz, Cloud P; Gokhale, Prafulla C; Jänne, Pasi A.
Afiliação
  • Haikala HM; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lopez T; Harvard Medical School, Boston, Massachusetts.
  • Köhler J; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Eser PO; Harvard Medical School, Boston, Massachusetts.
  • Xu M; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zeng Q; Harvard Medical School, Boston, Massachusetts.
  • Teceno TJ; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ngo K; Harvard Medical School, Boston, Massachusetts.
  • Zhao Y; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ivanova EV; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bertram AA; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Leeper BA; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chambers ES; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Adeni AE; Harvard Medical School, Boston, Massachusetts.
  • Taus LJ; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kuraguchi M; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kirschmeier PT; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Yu C; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Shiose Y; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kamai Y; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Qiu Y; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Paweletz CP; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gokhale PC; Global Oncology R&D, Daiichi Sankyo, Basking Ridge, New Jersey.
  • Jänne PA; DS Oncology Function Biomarker and Translational Research Department, Daiichi Sankyo, Shinagawa R&D Center, Tokyo, Japan.
Cancer Res ; 82(1): 130-141, 2022 01 01.
Article em En | MEDLINE | ID: mdl-34548332
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Receptor ErbB-3 / Receptores ErbB / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Receptor ErbB-3 / Receptores ErbB / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article